Jan 23, 2019 Lasmiditan Delivers Migraine Relief After Two Hours Without High Cardiovascular Risk Lasmiditan Delivers Migraine Relief After Two Hours Without High Cardiovascular RiskThe randomized, double-blind, placebo-controlled study was published in Neurology on November 16, just two days after Eli Lilly announced its ... read morePublished on 2019-01-23